The FDA Just Approved Remdesivir for Infants and Young Children

In a news release, the FDA explained that part of the rationale behind the approval of Veklury for infants and young children is that there is no alternative “safe and effective treatment,” including the COVID-19 experimental “vaccine,” which is currently not approved for children under five. Patricia Cavazzoni, M.D., director of the agency’s Center for Drug Evaluation and Research, remarked:

“As COVID-19 can cause severe illness in children, some of whom do not currently have a vaccination option, there continues to be a need for safe and effective COVID-19 treatment options for this population. Today’s approval of the first COVID-19 therapeutic for this population demonstrates the agency’s commitment to that need.”